Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2
暂无分享,去创建一个
F. Dabis | S. Urien | D. Ekouevi | S. Blanche | A. Pruvost | E. Arrivé | J. Treluyer | D. Hirt | S. Benaboud | F. Théodoro | P. Coffie | Divine Avit
[1] J. Stringer,et al. Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study , 2010, PLoS medicine.
[2] B. Clotet,et al. Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir , 2009, Antimicrobial Agents and Chemotherapy.
[3] F. Dabis,et al. Population Pharmacokinetics of Tenofovir in HIV‐1‐Infected Pregnant Women and Their Neonates (ANRS 12109) , 2009, Clinical pharmacology and therapeutics.
[4] M. Fowler,et al. Antiretroviral Concentrations in Breast-Feeding Infants of Mothers Receiving Highly Active Antiretroviral Therapy , 2008, Antimicrobial Agents and Chemotherapy.
[5] B. Chi,et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial , 2007, The Lancet.
[6] B. Masquelier,et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. , 2007, International journal of epidemiology.
[7] S. Lagakos,et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.
[8] B. Kearney,et al. Pharmacokinetics of Tenofovir in Breast Milk of Lactating Rhesus Macaques , 2005, Antimicrobial Agents and Chemotherapy.
[9] F. Rousseau,et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.
[10] F. Dabis,et al. Population Pharmacokinetics of Emtricitabine in HIV-1 infected Pregnant Women and their neonates ( ANRS 12109 ) , 2008 .